Anticoagulation stewardship: Descriptive analysis of a novel approach to appropriate anticoagulant prescription.

anticoagulants atrial fibrillation drug interactions pharmacist prescriptions venous thromboembolism

Journal

Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 01 12 2021
revised: 08 05 2022
accepted: 15 05 2022
entrez: 3 10 2022
pubmed: 4 10 2022
medline: 4 10 2022
Statut: epublish

Résumé

Anticoagulants are a leading cause of morbidity among hospitalized patients, with prescription errors commonly reported. Literature surrounding anticoagulation stewardship is scarce despite its documented effectiveness in the antimicrobial realm. To determine the proportion of accepted recommendations on inappropriate anticoagulant prescriptions suggested by a multidisciplinary anticoagulation stewardship program (ASP). We conducted a descriptive cohort study of hospitalized patients using therapeutic anticoagulation at a large Canadian tertiary care center between September 1, 2019, and February 28, 2020. A multidisciplinary ASP, composed of physicians and pharmacists, was implemented on June 1, 2019. Patient-, anticoagulant-, and admission-related characteristics were collected. The primary outcome was the proportion of accepted ASP team recommendations by the prescribing team. A total of 381 patients were enrolled during the study period, resulting in 553 anticoagulant reviews (1.56 reviews/patient) by the ASP. The most common indications for anticoagulation were atrial fibrillation (n = 276, 72%) and venous thromboembolism (n = 84, 22%). Direct oral anticoagulants were most frequently prescribed (n = 253, 67%), followed by vitamin K antagonists (n = 88, 23%). Among the reviewed prescriptions, 355 of 553 (64%) generated a recommendation; 299 of 355 (84%) recommendations were accepted by the treating team. Dose adjustments were the leading category of recommendations (31%), followed by alerts regarding drug interactions (19%). Inpatient anticoagulant prescriptions were optimized following recommendations by the ASP team. The most frequent types of prescription changes concerned dose adjustments and drug interactions. Further research is required to assess the effect of an ASP on clinical outcomes.

Sections du résumé

Background UNASSIGNED
Anticoagulants are a leading cause of morbidity among hospitalized patients, with prescription errors commonly reported. Literature surrounding anticoagulation stewardship is scarce despite its documented effectiveness in the antimicrobial realm.
Objective UNASSIGNED
To determine the proportion of accepted recommendations on inappropriate anticoagulant prescriptions suggested by a multidisciplinary anticoagulation stewardship program (ASP).
Methods UNASSIGNED
We conducted a descriptive cohort study of hospitalized patients using therapeutic anticoagulation at a large Canadian tertiary care center between September 1, 2019, and February 28, 2020. A multidisciplinary ASP, composed of physicians and pharmacists, was implemented on June 1, 2019. Patient-, anticoagulant-, and admission-related characteristics were collected. The primary outcome was the proportion of accepted ASP team recommendations by the prescribing team.
Results UNASSIGNED
A total of 381 patients were enrolled during the study period, resulting in 553 anticoagulant reviews (1.56 reviews/patient) by the ASP. The most common indications for anticoagulation were atrial fibrillation (n = 276, 72%) and venous thromboembolism (n = 84, 22%). Direct oral anticoagulants were most frequently prescribed (n = 253, 67%), followed by vitamin K antagonists (n = 88, 23%). Among the reviewed prescriptions, 355 of 553 (64%) generated a recommendation; 299 of 355 (84%) recommendations were accepted by the treating team. Dose adjustments were the leading category of recommendations (31%), followed by alerts regarding drug interactions (19%).
Conclusion UNASSIGNED
Inpatient anticoagulant prescriptions were optimized following recommendations by the ASP team. The most frequent types of prescription changes concerned dose adjustments and drug interactions. Further research is required to assess the effect of an ASP on clinical outcomes.

Identifiants

pubmed: 36186105
doi: 10.1002/rth2.12758
pii: S2475-0379(22)02341-X
pmc: PMC9510439
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e12758

Informations de copyright

© 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).

Références

Isr J Health Policy Res. 2019 Feb 01;8(1):19
pubmed: 30709417
Thromb Haemost. 2017 Jun 28;117(7):1283-1288
pubmed: 28594426
J Am Heart Assoc. 2021 Dec 21;10(24):e022758
pubmed: 34796718
Br J Clin Pharmacol. 2020 Mar;86(3):533-547
pubmed: 31631392
Clin Ther. 2015 Nov 1;37(11):2506-2514.e4
pubmed: 26481493
J Am Coll Cardiol. 2017 Jun 13;69(23):2779-2790
pubmed: 28595692
J Am Coll Cardiol. 2016 Dec 20;68(24):2597-2604
pubmed: 27978942
New Horiz. 1996 Aug;4(3):370-6
pubmed: 8856755
Int J Clin Pharm. 2019 Jun;41(3):691-699
pubmed: 31020598
J Am Heart Assoc. 2020 Mar 17;9(6):e014108
pubmed: 32146898
J Am Heart Assoc. 2020 Nov 17;9(22):e016949
pubmed: 33150804
JAMA. 2021 Oct 05;326(13):1299-1309
pubmed: 34609453
Clin Infect Dis. 2016 May 15;62(10):e51-77
pubmed: 27080992
PLoS One. 2020 Jun 25;15(6):e0235048
pubmed: 32584857
Br J Clin Pharmacol. 2020 Aug;86(8):1567-1574
pubmed: 32090369
Pharmacy (Basel). 2018 May 14;6(2):
pubmed: 29757930
J Thromb Haemost. 2014;12(3):320-8
pubmed: 24330006
Clin Infect Dis. 2010 Nov 1;51(9):1074-80
pubmed: 20879856
J Thromb Thrombolysis. 2021 Feb;51(2):413-418
pubmed: 32666429
J Am Heart Assoc. 2020 Jul 7;9(13):e017559
pubmed: 32538234
Lancet. 2014 Mar 15;383(9921):955-62
pubmed: 24315724

Auteurs

Maral Koolian (M)

Division of General Internal Medicine, Jewish General Hospital McGill University Montreal Quebec Canada.
Department Medicine, Jewish General Hospital McGill University Montreal Quebec Canada.
Centre for Clinical Epidemiology of the Lady Davis Institute for Medical Research Jewish General Hospital Montreal Quebec Canada.

Daniel Wiseman (D)

Department Medicine, Jewish General Hospital McGill University Montreal Quebec Canada.

Helen Mantzanis (H)

Department of Pharmacy, Jewish General Hospital McGill University Montreal Quebec Canada.

Nikki Kampouris (N)

Department of Pharmacy, Jewish General Hospital McGill University Montreal Quebec Canada.

Ryan S Kerzner (RS)

Department of Pharmacy, Jewish General Hospital McGill University Montreal Quebec Canada.

Susan R Kahn (SR)

Division of General Internal Medicine, Jewish General Hospital McGill University Montreal Quebec Canada.
Department Medicine, Jewish General Hospital McGill University Montreal Quebec Canada.
Centre for Clinical Epidemiology of the Lady Davis Institute for Medical Research Jewish General Hospital Montreal Quebec Canada.

Classifications MeSH